Viruses are tiny, infectious agents that can only replicate inside the cells of living organisms. To replicate, viruses must first enter a cell, then hijack the cell's machinery to make copies of themselves. Once enough copies have been made, the viruses burst out of the cell, destroying it in the process.
The viral protein studied by the Washington University researchers, called NS1, is produced by the influenza virus. NS1 plays a critical role in the virus's replication cycle by preventing the host cell from detecting and destroying the virus.
NS1 does this by binding to a protein called RIG-I, which is part of the cell's immune system. RIG-I normally detects viral RNA and triggers an immune response, but NS1 prevents RIG-I from doing its job.
The Washington University researchers found that NS1 binds to RIG-I in a way that blocks the protein's ability to interact with viral RNA. This means that RIG-I cannot trigger an immune response, and the virus is able to replicate unchecked.
The researchers also found that NS1 can bind to other proteins in the cell that are involved in the immune response. This suggests that NS1 may have multiple ways to block the immune system and promote virus replication.
The findings of this study could help scientists develop new antiviral therapies that target NS1. By blocking NS1's ability to bind to RIG-I and other proteins, scientists may be able to prevent the virus from replicating and spreading.
This could lead to new treatments for viral infections, including COVID-19, which is caused by a coronavirus. There are currently no effective antiviral treatments for COVID-19, so the development of new therapies is urgently needed.
